In an open phase 1 trial (14 patients with pulmonary fibrosis), D+Q was feasible and improved walking distance and speed, without change in lung function.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).